Key clinical point: Brentuximab vedotin (Bv), given before and after standard chemotherapy, improved survival in untreated Hodgkin lymphoma.
Major finding: Two-year PFS was 84% for patients treated additionally with Bv, compared with 50% historically for standard therapy.
Study details: A prospective phase 2 study involving 48 elderly patients with Hodgkin lymphoma.
Disclosures: Seattle Genetics supported the investigator-initiated trial. Dr. Evens reported consulting or advisory relationships with Seattle Genetics and several other companies.
Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.
This Week's Must Reads
Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005
TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885
Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291
Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04
Outcomes better in TNBC with adjuvant chemotherapy within 30 days of surgery, Morante Z et al., SABCS 2018 Abstract GS2-05
Must Reads in Hodgkin Lymphoma
Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.
Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.
PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.
Treatments for Advanced Hodgkin’s Lymphoma Studied, N Engl J Med; 2018 Jan 25; Connors, Jurczak, et al